India's Zydus Cadila Launches Cancer Drug Nudoxa
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Ahmedabad, India-based Zydus Cadila said it will begin manufacturing and marketing cancer treatment Nudoxa, with patents in India and South Africa for a gentler variant of liposomal doxorubicin that mitigates side effects such as skin eruptions on the hands and feet
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)